Tag: CSE:AGN

May 26, 2020

Pharmaceutical Companies Repurposing Drugs to Accelerate Growth

The drug development process can be incredibly costly, both in terms of the financial commitment required and the time necessary...
May 15, 2020

Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, is pleased to announce that it has submitted for ethics approval in...
May 6, 2020

Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Algernon Pharmaceuticals has received ethics approval for the planned Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil).
May 5, 2020

Algernon Amends Terms of Private Placement Offering of Special Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) has amended certain terms of its brokered private placement, being conducted...
May 1, 2020

Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants

Algernon Pharmaceuticals a clinical stage pharmaceutical development company, has entered into an agreement with Mackie Research Capital Corporation
April 30, 2020

Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) has received a No Objection Letter from Health Canada to proceed...
April 29, 2020

Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

Algernon is pleased to announce that Dr. Mark Williams will be making a presentation entitled “The Science of Ifenprodil” on...